Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$20.56-0.58%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Primary pillar under pressure — Operating losses reduced to about -$34M: metric not reported.
Syndax is growing revenue fast, from $20M to $64.9M in a year. They are cutting operating losses, improving from -$69.4M to -$34.2M. The company raised $250M in convertible notes to strengthen its finances. These moves support a recovery in this clinical-stage biotech.
Syndax remains unprofitable with losses expected to continue. Revenue growth may slow and losses may widen again. The company’s heavy debt and equity sales could pressure the stock. Clinical risks and execution challenges remain high.
The stock trades about 32% below our fair value near $34. Analysts expect 76% revenue growth next year. Our fair value is 13% below the Street median, reflecting cautious optimism. The market prices in strong growth but also elevated risk.
Breaks if: Failure to raise or maintain $250 million in convertible notes
Breaks if: Operating losses worsen beyond -$34.2 million
Revenue falls below $380 million in FY25
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. SNDX is focused on advancing its commercial products and expanding its pipeline, but it faces risks from market conditions and execution challenges.
The market currently prices SNDX as relatively cheap compared to its peers, with an expectations gap indicating that investors may not fully anticipate future performance. The valuation reflects a justified stance, suggesting that the current price does not overly reflect the company's potential.
Management is on track with its priorities, showing strong revenue growth for its products and ongoing clinical trials. However, the company remains loss-making, and there is an elevated risk of missing earnings expectations, which could impact future performance.
The long-term thesis hinges on the company's ability to maintain commercial growth and successfully advance its clinical trials. Additionally, external factors such as sector performance and economic conditions will play a significant role in shaping the outlook.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss raised concerns about performance. Sales growth is not translating into stock performance, which is troubling.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, SNDX's performance will depend on its execution and market conditions. Not investment advice.